血清壳多糖酶3样蛋白1、肝纤维化4项及AFP的检测在不同肝脏疾病中的应用价值探讨

目的探讨血清壳多糖酶3样蛋白1(CHI3L1)、肝纤维化4项及甲胎蛋白(AFP)在不同肝脏疾病中的应用价值。方法选取172例符合条件的慢性乙型肝炎病毒感染者,分为慢性乙型肝炎组、肝硬化组和肝癌组。收集同期健康体检者30例作为正常对照组。比较各组间指标的差异,采用受试者工作特征(ROC)曲线分析各指标鉴别诊断效能。采用Spearman秩相关分析各指标与疾病严重程度的相关性。结果血清CHI3L1及肝纤维化4项在肝硬化组和肝癌组明显高于慢性乙型肝炎组和正常对照组(P <0.05)。血清AFP浓度在肝癌组明显高于其他各组,上述差异均有统计学意义(P <0.01),其诊断肝癌的AUC为0.912。ROC曲线分析显示CHI3L1在肝硬化组和慢性乙型肝炎组,慢性乙型肝炎组和正常对照组之间的鉴别诊断效能较好,AUC分别为0.853和0.845。Spearman相关性分析显示肝脏疾病的严重程度与各血清学指标均呈正相关(P <0.05)。结论 CHI3L1、肝纤维化4项及AFP的检测可以辅助诊断慢性肝炎及其肝纤维化导致的肝硬化等不同肝脏疾病,值得在临床推广和进一步的研究。     

The relationship between plasma apolipoprotein A-Ⅳ levels and coronary heart disease

Objective To evaluate the relationship between plasma apoA-Ⅳ levels and coronary atheros clerosis and to explore its relation to other risk factors.Methods Using ELISA techniques, plasma apoA-Ⅳ levels were quantified in 181 patients w ho underwent coronary angiography (CAG).Patients were divided according to the ir coronary status into a coronary heart disease (CHD) group (stenotic lesion on CAG, n=118) and a control group (normal CAG, n=63).The severity of athero sclerosis was assessed by stenosis scoring of the different lesions.Other para meters, including apoA-Ⅰ,apoB, Lp(a), HDL-C, LDL-C, TG, and T C, were measured as well.Univariate, logistic regression analyses were used to define the relationship between coronary atherosclerosis and plasma apoA-Ⅳ levels.Results When compared with the control group, plasma apoA-Ⅳ levels were found to be lo wer in the CHD group.There was a weak negative correlation between plasma apoA -Ⅳ levels and the severity of coronary atherosclerosis.ApoA-Ⅳ was found to be a relatively independent risk factor for CHD.We also found a positive corr elation between apoA-Ⅳ and triglyceride levels.Conclusions ApoA-Ⅳ may be important in the prediction of CHD and coronary atherosclerosis severity.It may also play an important role in the metabolism of triglycerides .     

检测Ⅳ型胶原蛋白直接双抗夹心法的建立与评价

目的 :建立血清 型胶原蛋白 (COL - )浓度测定的直接双抗夹心法 ,为临床诊断肝纤维化提供一种新的指标。方法 :采用本科室自制的 COL - 单克隆酶标抗体、多克隆抗体建立的直接双抗夹心法 ,同时采用日本试剂盒测定 6 0份正常和肝脏病人血清 COL- 浓度做对照比较。结果 :两种方法无显著性差异 (P>0 .0 5 ,t=0 .16 6 ) ;两法相关分析 ,γ=0 .834,回归方程为 Y=0 .5 9X+ 70 .874。结论 :直接双抗夹心法测定血清 COL- 操作简便、特异、准确 ,可作为辅助诊断肝纤维化的可靠指标 ,并可在临床推广应用     

血清Ⅲ、Ⅳ型胶原及板层素对肝纤维化的诊断价值

目的：探索诊断早期肝纤维化的敏感指标。方法：用放射免疫法检测２３６例各型肝病患者血清Ⅲ型胶原（ＴｐｙｅⅢｃｏｌａｇｅｎ,ＰＣⅢ）、Ⅳ型胶原（ＴｐｙｅⅣｃｏｌａｇｅｎ,Ⅳ－Ｃ）和板层素（Ｌａｍｉｎｉｎ,ＬＮ）水平。结果：各类肝病患者血清ＰＣⅢ、Ⅳ－Ｃ和ＬＮ水平随病情进展而逐渐升高。以ＰＣⅢ≥１３５μｇ／Ｌ、Ⅳ－Ｃ≥１３０μｇ／Ｌ为诊断肝纤维化的临界点,其敏感度、特异性、准确率分别达８０％以上。结论：表明ＰＣⅢ、Ⅳ－Ｃ及ＬＮ可作为肝纤维化诊断较为敏感的指标,其中Ⅳ－Ｃ对早期肝纤维化的诊断优于ＰＣⅢ及ＬＮ,对肝癌的诊断有一定意义     

贞芪扶正口服液的质量标准

目的制订贞芪扶正口服液质量标准。方法用薄层色谱法鉴别黄芪、女贞子、白术 ;用香草醛 硫酸比色法测定黄芪甲苷的含量。结果平均回收率为 98 95 % ,RSD为 0 81 % (n =5 )。结论建立的方法可控制贞芪扶正口服液的质量     

金荞麦提取物抑制肿瘤细胞侵袭、转移和HT-1080细胞产生Ⅳ型胶原酶的研究

目的探讨金荞麦提取物对肿瘤细胞侵袭和转移的影响。方法以人工重组基底膜及小鼠黑色素瘤高转移株自发性肺转移模型观察了金荞麦提取物对Ｂ１６－ＢＬ６细胞的体外抗侵袭活性和体内抗转移作用；用聚丙烯酰胺凝胶电泳法进一步观察了其对人纤维肉瘤ＨＴ－１０８０细胞Ⅳ型胶原酶的产生及活性的影响；同时用ＷＳＴ法观察了该药的细胞毒性。结果金荞麦提取物在１００ｍｇＬ－１剂量下能明显抑制Ｂ１６－ＢＬ６细胞侵袭；在２００ｍｇｋｇ－１剂量下能有效抑制Ｂ１６－ＢＬ６黑色素瘤细胞在Ｃ５７／ＢＬ６小鼠体内自发性肺转移。该药对Ｂ１６－ＢＬ６和ＨＴ－１０８０细胞无明显细胞毒作用。该药能抑制ＨＴ－１０８０细胞Ⅳ胶原酶的产生，但对酶的活性无明显影响。结论金荞麦提取物具有明显的抗癌侵袭和转移的作用。     

复方中药糖耐康对高糖诱导大鼠系膜细胞外基质的影响，

目的观察复方中药糖耐康对高糖环境下大鼠系膜细胞外基质的纤维连接蛋白（FN）、Ⅳ型胶原蛋白（IV—C）及转化生长因子TGF-β1。含量的影响。方法大鼠肾小球系膜细胞按1×10^5孔接种24孔板,实验分为6组：正常葡萄糖组、高糖对照组、中药糖耐康高、中、低浓度干预组、西药吡格列酮组。每组设平行孔4孔,培养24h后检测指标。采用双抗夹心酶联免疫吸附（ELISA）法检测FN、IV-C及TGF-β1,含量。结果与空白对照组比较,高糖模型组MCs的上清中的FN、IV-C、TGF-β1含量均显著升高,差异有统计学意义（P均〈0．05）;与高糖组比较,治疗组FN、IV-C、TGF-β1,含量均显著降低,差异有统计学意义（P〈0．01）;与吡格列酮组比较,糖耐康中、低剂量组FN、IV-C、TGF-β1。含量差异有统计学意义（P〈0．01）,而糖耐康高剂量组各指标差异无统计学意义（P〉0．05）。结论糖耐康对糖尿病肾病肾脏的保护作用之一,是通过抑制系膜细胞外基质中FN、IV-C、TGF-β,的分泌、产生,从而抑制了系膜细胞的增值,起到保护糖尿病患者。肾脏的作用。     

Ⅳ期非小细胞肺癌预后因素分析

目的：回顾分析Ⅳ期非小细胞肺癌患者（NSCLC）的预后因素,指导临床个体规范化的治疗。方法：采用Kaplan Meier生存分析以及COX回归模型分析57例Ⅳ期初治NSCLC患者临床特征,如年龄、性别、吸烟指数、病理类型以及治疗前血浆中CEA和Cyfra21-1的水平等以及治疗相关因素与生存率的关系,筛选Ⅳ期NSCLC患者预后相关因素。结果：单因素分析表明,患者的年龄、吸烟指数、KPS评分、治疗前血浆Cyfra21-1水平以及化疗与否、化疗周期数与Ⅳ期NSCLC患者的生存率有关。多因素分析表明,Cyfra21-1、KPS评分、化疗周期是独立的预后因素。结论：治疗前血浆中Cyfra21-1的水平,KPS评分以及化疗周期数为Ⅳ期NSCLC患者的独立预后因素。无化疗禁忌症的Ⅳ期NSCLC患者积极规范合理的治疗能延长患者生存期,具有重要的临床意义。     

Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy

Parkin, an E3 ubiquitin ligase, plays a role in maintaining mitochondrial homeostasis through targeting damaged mitochondria for mitophagy. Accumulating evidence suggests that the acetylation modification of the key mitophagy machinery influences mitophagy level, but the underlying mechanism is poorly understood. Here, our study demonstrated that inhibition of histone deacetylase (HDAC) by treatment of HDACis activates mitophagy through mediating Parkin acetylation, leading to inhibition of cervical cancer cell proliferation. Bioinformatics analysis shows that Parkin expression is inversely correlated with HDAC2 expression in human cervical cancer, indicating the low acetylation level of Parkin. Using mass spectrometry, Parkin is identified to interact with two upstream molecules, acetylase acetyl-CoA acetyltransferase 1 (ACAT1) and deacetylase HDAC2. Under treatment of suberoylanilide hydroxamic acid (SAHA), Parkin is acetylated at lysine residues 129, 220 and 349, located in different domains of Parkin protein. In in vitro experiments, combined mutation of Parkin largely attenuate the interaction of Parkin with PTEN induced putative kinase 1 (PINK1) and the function of Parkin in mitophagy induction and tumor suppression. In tumor xenografts, the expression of mutant Parkin impairs the tumor suppressive effect of Parkin and decreases the anticancer activity of SAHA. Our results reveal an acetylation-dependent regulatory mechanism governing Parkin in mitophagy and cervical carcinogenesis, which offers a new mitophagy modulation strategy for cancer therapy.     

反相高效液相色谱法测定黄芪中黄芪甲苷的含量

 目的建立黄芪中主要有效成分黄芪甲苷的RP HPLC。方法采用Kromasil C₁₈(250 mm×4.6 mm,5 μm)色谱柱,乙腈 水(30∶70)为流动相,检测波长为203nm,以卡马西平为内标。结果线性范围为0.1～1.0 mg·mL^-1,三水平的平均回收率(%)分别为82.1,85.4和88.4,RSD(%)分别为2.88,1.31和2.67。结论本法准确,可靠,适用于黄芪药材的质量控制。